Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
11.50    -0.50 (-4.17%)
Bid:
11.00
Ask:
12.00
Spread: 1.00 (9.091%)
Market Cap: £14.39m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

30 Apr 2007 07:03

Fabian Romania Property Fund Ltd30 April 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or the "Fund") Fabian Romania announces the purchase of a €60 million office building inBucharest Fabian Romania has reached agreement to purchase its fourth office project, theCubic office development (the "Cubic Centre"), in Bucharest. The Cubic Centrewill be a class A office building with a gross area of approximately 44,000square metres, located in North Bucharest. The building is being developed bythe Kendama, an experienced local developer in Romania. Construction hascommenced and completion is anticipated in the second quarter of 2009. The Cubic Centre will upon completion of construction provide a net lettableoffice area of 27,000 square metres over 12 floors, together with 533 carspaces. The building is located in a prominent location in the Pipera districtof North Bucharest and is likely to attract international tenants seeking classA office space. Vacancy rates for class A office space in in Bucharest are lessthan 3%. The acquisition is due to complete, subject to certain conditions, in twostages. The Fund will pay a first instalment of €12.25 million, of which €5million has already been paid in the form of a secured loan. At practicalcompletion of the building by the developer, the Fund will pay the finalinstalment based upon a forward purchase yield of 7.4% - 7.8% applied to rentsachieved. Based upon current rental estimates, the total value of thetransaction is estimated to be approximately of €60 million. The total equityrequirement for the fund is estimated to be €12 million. Commenting on the transaction, Mark Holdsworth, Managing Director of FabianCapital, the Investment Advisor to the Fund said: "We are delighted that the Fund has sealed its first investment since Admissionto AIM on favourable terms in what is a highly competitive market. The CubicCentre will provide a high quality addition to the Fund's portfolio of officebuildings. It will also give diversification geographically within the city bothin terms of building type and expected tenant mix." Mark Owen, Director responsible for acquisitions comments: "The new office development is in a prominent location in the rapidly expandingoffice location of the northern Pipera district of the City. This area will befurther enhanced by the new motorway link into the City. The Cubic Centre,which is already under construction on a fixed price basis, is well positionedto capitalise on the demand for Class A office space expected. We are already inearly discussions with a number of quality tenants seeking to upgrade theiroffice accommodation." The lead advisers on the transaction were Eurisko (property agent), WSP(technical advisers) and NNDKP (legal adviser). END For Comments:Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLP +44 20 7936 3000James Lewis Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
18th Mar 20257:00 amRNSPlacing to raise approximately £1.17 million
27th Feb 20257:00 amRNSContract win
31st Jan 20257:00 amRNSOptiMAL R&D Update
4th Dec 202411:31 amRNSApproval of Grant Funding Application
19th Nov 20247:00 amRNSHalf-year Report
16th Oct 20241:23 pmRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSIssue of shares to non-executive directors
8th Oct 202412:32 pmRNSResult of AGM
8th Oct 20247:00 amRNSAGM statement and trading update
2nd Oct 20247:00 amRNSBlock admission six monthly return
12th Sep 20249:54 amRNSNotice of AGM
9th Sep 202412:35 pmRNSDirector/PDMR Shareholding
5th Sep 202412:15 pmRNSDirector/PDMR Shareholding
5th Sep 20247:00 amRNSFinal Results
22nd Jul 202412:54 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSTrading update
23rd May 20247:00 amRNSNew contract with existing client
2nd May 20247:00 amRNSInvestor presentation
30th Apr 20247:00 amRNSYear-end trading statement
16th Apr 20247:00 amRNSChange of auditor
15th Apr 20247:00 amRNSContract to develop a bespoke OptiPhage library
2nd Apr 20242:34 pmRNSBlock admission six monthly return
28th Mar 20245:00 pmRNSTotal Voting Rights
11th Mar 20243:04 pmRNSHolding(s) in Company
11th Mar 20249:10 amRNSHolding(s) in Company
8th Mar 20243:09 pmRNSHolding(s) in Company
5th Mar 202410:40 amRNSResult of General Meeting and Total Voting Rights
29th Feb 20245:00 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSFirst purchase order under MSA
14th Feb 20247:15 amRNSGrant of options and issue of shares to directors
14th Feb 20247:00 amRNSPlacing to raise £1,375,000
6th Feb 20247:00 amRNSFollow-on project award and R&D update
1st Feb 20247:00 amRNSHMRC R&D tax credit
4th Dec 202312:26 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSHalf-year Report
28th Nov 20237:00 amRNSOptiMAL collaboration agreement
9th Nov 20237:00 amRNSHalf year trading update
27th Oct 202311:57 amRNSResult of AGM
4th Oct 20232:45 pmRNSBlock admission six monthly return
29th Sep 20237:00 amRNSFinal Results
29th Aug 20237:00 amRNSUpdate on AI/ML-Ab service offering
24th Aug 20237:00 amRNSAppointment of interim CFO
21st Aug 20237:00 amRNSUpdate on AI/ML-Ab™ antibody discovery service
14th Aug 20237:00 amRNSUpdate on restructure and cost savings
30th Jun 20235:00 pmRNSTotal Voting Rights
16th Jun 202310:09 amRNSHolding(s) in Company
15th Jun 20239:45 amRNSHolding(s) in Company
13th Jun 20232:44 pmRNSHolding(s) in Company
12th Jun 20233:34 pmRNSHolding(s) in Company
12th Jun 202311:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.